Key Takeaways
1. A shared measurement standard. A core outcome set defines the minimum outcomes every CKD pharmacist trial should report, letting pharmacists compare interventions that were previously impossible to line up because studies measured different things.
2. Patient priorities can diverge from clinician assumptions. People living with CKD rated dialysis adherence, graft function, and proteinuria screening as critical; researchers and pharmacists prioritized polypharmacy instead—a reminder to weigh patient-defined outcomes, not just clinical ones.
3. Consistency is the point. Because past CKD pharmacist studies measured outcomes inconsistently, adopting the set reduces heterogeneity and reporting bias and makes evidence easier to synthesize into practice.
In an interview with Pharmacy Times, Ashkon Ardavani, PharmD, PhD, a research associate at the University of Leicester whose PhD investigated the role of the pharmacist in managing chronic kidney disease (CKD), explained what a core outcome set is and why stakeholders often disagree on which outcomes matter most.
A core outcome set, Ardavani said, is a minimum agreed group of outcomes that should be reported in all trials for a given clinical area, reflecting what matters to patients, researchers, and health care professionals. Its purpose is to facilitate research synthesis, reduce heterogeneity and reporting bias, and ensure the most important outcomes are consistently evaluated. He argued this should reshape how pharmacists think about their work in CKD studies, because prior reviews of pharmacist interventions have shown a wide range of outcomes reported across trials, with the same outcomes rarely measured consistently. For pharmacists, he said, the value is practical: a shared set enables direct comparison of how effective different interventions are at improving the outcomes that matter.
Ardavani also detailed where stakeholder groups diverged. Participants rated each outcome's importance on a 9-point Likert scale, with 7 to 9 signaling critical importance. In the first Delphi round, people living with CKD viewed acute kidney function, dialysis adherence, and graft function as critically important, while researchers, pharmacists, and other health care professionals did not. The reverse held for polypharmacy, which clinicians and researchers flagged as critical but patients did not. In the second round, people with CKD rated proteinuria screening as critical, whereas the professional groups did not.
For pharmacists, the takeaway is that the outcomes patients prioritize can differ meaningfully from those clinicians assume matter—a gap the core outcome set is designed to surface and standardize so that future CKD intervention trials measure what is relevant to the people receiving care.
REFERENCE
